Last reviewed · How we verify

Prostatic carcinoma - palliative therapy of advanced disease — Treatment Landscape & Competitive Intelligence

Prostatic carcinoma - palliative therapy of advanced disease (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prostatic carcinoma - palliative therapy of advanced disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Menest Estrogens, Esterified Pfizer Inc. Estrogen Estrogen receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 1 drug in Prostatic carcinoma - palliative therapy of advanced disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prostatic carcinoma - palliative therapy of advanced disease:

Cite this brief

Drug Landscape (2026). Prostatic carcinoma - palliative therapy of advanced disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prostatic-carcinoma-palliative-therapy-of-advanced-disease. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing